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Abstract
Alpha-1-antitrypsin (AAT) plays an important role in the pathogenesis of emphysema, the pathological lesion under-
lying the majority of the manifestations of Chronic Obstructive Pulmonary Disease (COPD). In this study we tested
the hypothesis that common AAT polymorphisms influence the risk of developing COPDs. We investigated PiM1
(Ala213Val), PiM2 (Arg101His), PiM3 (Glu376Asp), PiS (Glu264Val) and PiZ (Glu342Lys) SERPINA1 alleles in 100
COPD patients and 200 healthy controls. No significant differences were observed in allele frequencies between
COPD patients and controls, neither did haplotype analysis show significant differences between the two groups. A
cross-sectional study revealed no significant relationship between common SERPINA1 polymorphisms (PiM1,
PiM2, PiM3) and the emphysematous type of COPD. In addition, FEV1 annual decline, determined during a two-year
follow up period, revealed no difference among carriers of the tested polymorphisms.
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Chronic obstructive pulmonary disease (COPD), a
heterogeneous disorder, is a major cause of respiratory dis-
ability and the fourth major cause of death world-wide
(World Health Organization, 2000). Exposure to cigarette
smoke is recognized as the main environmental risk factor
involved(Teramoto,2007).SevereAlpha-1-antitrypsinde-
ficiency (AATD) is a proven genetic risk factor, with about
80% of the subjects develop the disease between 30 to 40
years or earlier, in spite of only 1%-3% of COPD cases be-
ing due to severe AAT deficiency (Lomas and Silverman,
2001).
Alpha-1 antitrypsin (AAT) is a 52 kDa protein syn-
thesized primarily by hepatocytes. Its main function is to
inhibit the activity of neutrophile elastase in the lung. This
is a protease capable of destroying the major structural pro-
teinsofthealveolarwall.PlasmaAATdeficiencyresultsin
accelerated elastin degradation, leading to a loss of ventila-
tor function and the subsequent development of emphy-
sema (Mahadeva and Lomas, 1998). The AAT coding gene
SERPINA1 is highly polymorphic, with more than 125
SNPsreportedinpublicdatabases,itsmostcommonalleles
being the normal M alleles and its subtypes (PiM1Ala,
PiM1Val, PiM2, PiM3), besides the deficient alleles PiS
and PiZ (Crystal, 1990). About 95% of the individuals with
severe AATD are homozygous for PiZt (ATS/ERS, 2003),
whereas PiSZ heterozygotes have approximately one-third
of the normal AAT serum level, besides being highly prone
to the development of diseases (Dahl et al., 2005). COPD
risk among PiMZ heterozygotes has been previously ana-
lyzed with controversial results. Meta-analysis indicates a
slight increase in risk of COPD in PiMZ individuals, with
no significant lung-function impairment, compared to
PiMM (Hersh et al., 2004).
A few studies on SERPINA1 common variants in
COPD have been reported, also with controversial results.
Matsuse et al. (1995), Shim (2001) and Kim et al. (2005)
did not find a significant association between PiM1, PiM2
or PiM3 alleles and COPD, whereas Kwok et al. (2004)
came across a significant increase in PiM1M3, PiM2M3
phenotypes and Gupta et al. (2005) reported a significant
increase for the PiM3 allele in COPD patients.
For a better understanding of the association between
SERPINA1 polymorphisms and COPD risk, we designed a
case-control study to detect differences in the frequencies
of common SNP alleles, haplotypes and genotypes, be-
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Short Communicationtween patients and controls in relation to common poly-
morphisms.
We also investigated the relationship between com-
mon SERPINA1 polymorphisms and main COPD clinical
manifestations. The major AAT neutrophile elastase inhib-
itory role is observed in alveolar parenchyma, the subse-
quent deficiency in plasma AAT concentration mainly
resulting in emphysema (Needham and Stockley, 2004).
We therefore compared the distribution of SERPINA1
polymorphismsbetweenthebronchialandemphysematous
types of COPD. In addition, COPD patients underwent a
two-year follow up, in order to evaluate the annual FEV1
(ForcedExpiratoryVolumein1s)declinerateinrelationto
commonSERPINA1alleles.FEV1isthehallmarkofCOPD
since it is affected by inflammation and remodeling of the
small airways as well as by emphysematous destruction of
the terminal airspaces (Weiss et al., 2003).
The study population consisted of 100 COPD sub-
jects who attended the Pneumology Department of Tahar
Sfar Hospital in Mahdia. Inclusion criteria for patients with
COPD were as follows: FEV1 < 80% of predicted value ad-
justed for age, weight and height, and an improvement in
FEV1 following bronchodilator inhalation < 12% of base-
line FEV1. Asthmatic patients showing a persistent airflow
obstructionwereexcluded.COPDphenotypeidentification
was based on chest radiographic and high-resolution com-
puterized tomography (HRCT) density findings. Clinical
characteristics of COPD patients are summarized in Table
S1. Follow-up examinations were conducted with patients
over a two-year period after baseline, with annually re-
peated spirometry tests. AATD individuals were excluded
from analysis. Two hundred healthy controls were enrolled
for the case-control study. They were recruited from a
blood donor’s cohort of Fattouma Bourguiba Hospital in
Monastir. Subjects with respiratory diseases, or any family
history of lung disease, were excluded. The distribution of
both patients and controls, according to demographic char-
acteristics, is shown in Table S2. Prior written informed
consent was obtained from all the subjects according to the
research protocol approved by the local ethics committee.
Total genomic DNA was extracted from peripheral
blood leucocytes by a phenol-chloroform method. PCR-
RFLP was employed for genotyping of PiM1 (Ala213
GCG  Val GTG), PiS (Glu264 GAA  Val GTA) and
PiZ (Glu342 GAG  Lys AAG) polymorphisms, as previ-
ously described (Ferrarotti et al., 2004). Briefly, we per-
formed PCR amplification using exon III primers to detect
theSand213Ala/ValvariantsandexonVfortheZvariant.
The reactions were carried out in an I-cycler Thermal Cy-
cler (Bio-Rad Laboratories).4Uo fSexAI and Hpy99I re-
striction enzymes (New England Biolabs) were used to
digest4LeachofexonIIIandexonVamplifiedDNA,re-
spectively. Genotyping of PiM2 (Arg101 CGT  His
CAT) and PiM3 (Glu376 GAA  Asp GAC) was per-
formed using hybridization probe analysis on Light Cycler
480 Roche apparatus (Roche Diagnostics), using a com-
mercial real-time assay (LightMix
®, Roche Diagnostics).
For each SNP, the primers flanking the SNP and the oligo-
nucleotide probes were designed and synthesized by the
manufacturer. The reaction mixture was prepared in a 96-
well PCR plate and processed according to manufacturer’s
instructions.Real-timePCRcyclingconditionswereasfol-
lows: 95 °C for 5 min, followed by 35 cycles of 95 °C for
10 s, 62 °C for 15 s and 72 °C for 15 s. After amplification,
PCR products were analyzed in a melting step of 40-95 °C.
Melting data were analyzed using the Genescanning mod-
ule of the LightCycler 480 software.
Annual FEV1 decline (ml/year) was calculated as the
difference between follow-up and baseline observed FEV1
values, divided by the number of months between the two
surveys, and multiplied by 12. SPSS v.10.0 software was
usedforstatisticalanalysis.Categoricalvariableswerepre-
sented as percentages, and intergroup differences were
compared using 
2 test or Fisher’s exact tests. Continuous
variables, described as mean  standard deviation, were
compared between the groups using Student’s t test. Hardy
Weinberg equilibrium tests and the estimation of allele and
haplotype frequencies were performed using HPlus v. 2.5
software.
The frequency of PiM1, PiM2, PiM3, PiS and PiZ al-
leles and genotypes between COPD patients and healthy
controls, was determined and compared (Table 1). Geno-
types for all the polymorphisms were within Hardy-
Weinberg proportions. There was no significant difference
in the genotypic and allelic distribution of normal PiM1,
PiM2 and PiM3 variants between subjects and controls.
DeficientPiSandPiZalleleswereonlyreportedinpatients,
with no apparent significant difference in relation to con-
trols. Ten haplotypes were selected for studying by the
expectationmaximizationprocedure(Table2),withnosig-
nificant differences being detected between patients and
controls by statistical comparison.
COPD patients were classified according to their pre-
dominant phenotype as follows: 53 subjects showed the
bronchial type of the disease (chronic bronchitis group;
mean age: 72.1  7.6 years); 47 presented a predominant
parenchymal destructive change (centrolobular and panlo-
bular emphysema groups; mean age: 69.5  12.2 years).
Univariate analysis was employed to verify whether there
were differences in COPD phenotypes among SERPINA1
genotypes (M1Ala containing vs. non M1Ala containing;
M2 containing vs. non M2 containing and M3 containing
vs.nonM3containing).TherelationshipbetweenFEV1an-
nual decline, smocking and BMI and COPD phenotypes
was also examined. No significant differences were de-
tected (Table 3).
Lungfunctionimpairmentinpatientswasassessedby
the annual FEV1 decline rate. After exclusion of AAT defi-
cient individuals, 96 patients underwent a two-year follow
up Annual FEV1 decline means were compared according
24 Denden et al.to age, smoking habits and SERPINA1 polymorphisms. No
significant relationship between annual FEV1 decline and
the tested variables was detected (Table 4).
Insummary,ourfindingsareconsistentwithobserva-
tions that there is no significant difference in the frequency
of common SERPINA1 variants in COPD patients, when
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Table 2 - SERPINA1 SNP haplotypes in COPD patients and controls.
Haplotype
a Patients Controls p
b OR 95% CI
GTAGA 0.48265 0.48773 1 1 N/A
GCAGA 0.21581 0.20572 0.864 1.04 0.67-1.61
ATAGC 0.18798 0.20385 0.683 0.91 0.56-1.46
GTAGC 0.08046 0.07999 0.974 0.99 0.50-1.96
ATAGA 0.01730 0.02270 0.663 0.77 0.24-2.50
ATTGA 0.00526 0.00000 N/A N/A N/A
ATAAC 0.00524 0.00000 N/A N/A N/A
GCAAA 0.00524 0.00000 N/A N/A N/A
GTAAA 0.00005 0.00000 N/A N/A N/A
ACAGC 0.00001 0.00000 N/A N/A N/A
aHaplotype frequency determined using expectation maximization me-
thod;
bFisher’s exact test.
Table 1 - SERPINA1genotypes and alleles in COPD patients and controls.
Genotype Allele HWE p
Ala213Val CC CT TT C T
Controls 0.63 0.33 0.04 0.79 0.21 0.699
a
Patients 0.63 0.31 0.06 0.78 0.22 0.418
a
p 0.764
a 0.887
a 0.516
a 0.671
a
OR (95% CI) 1.096 (0.718-1.672)
Arg101His GG GA AA G A
Controls 0.57 0.38 0.05 0.77 0.23 0.440
a
Patients 0.61 0.36 0.03 0.78 0.22 0.380
a
p 0.862
a 0.937
a 0.477
b 0.770
a
OR (95% CI) 0.939 (0.617-1.430)
Glu376Asp AA AC CC A C
Controls 0.49 0.45 0.06 0.73 0.28 0.217
a
Patients 0.53 0.39 0.08 0.73 0.27 0.648
a
p 0.348
a 0.413
a 0.497
a 0.798
a
OR (95% CI) 0.951 (0.645-1.402)
Glu264Val AA AT TT A T
Controls 1 0 0 1 0 N/A
Patients 0.98 0.02 0 0.99 0.01 0.917
a
p 0.193
b 0.193
b N/A 0.193
b
OR (95% CI) 10.199 (0.487-213.501)
Glu342Lys GG GA AA G A
Controls 1 0 0 1 0 N/A
Patients 0.98 0.02 0 0.99 0.01 0.917
a
p 0.193
b 0.193
b N/A 0.193
b
OR (95% CI) 10.199 (0.487-213.501)
HWE: Hardy-Weinberg Equilibrium.
aPearson’s 
2 test;
bFisher’s exact test.
Table 3 - Association studies of bronchial and emphysematous COPD
types with annual FEV1 decline (FEV1), cigarette smoking, body mass
index (BMI) and SERPINA1 genotypes.
Type/Class COPD phenotype p
CB CLE+PEL
FEV1 (ml/year) 171  137 232  239 0.243
a
Cumulative cigarette
consumption
59.41  29.22 51.97  28.68 0.230
a
BMI (kg/m
2) 24.33  3.70 22.77  5.21 0.117
a
M1Ala 0.41 0.53
No M1Ala 0.58 0.47 0.306
b
M2 0.45 0.45
No M2 0.54 0.54 1
b
M3 0.39 0.53
No M3 0.60 0.46 0.184
b
CB: Chronic Bronchitis; CLE: Centrolobular Emphysema; PLE: Panlo-
bular Emphysema; Cumulative cigarette consumption = number of packs
smoked per day multiplied by years of consumption. M1Ala: heterozy-
gous and homozygous for Ala213 allele; no M1Ala: homozygous for
Val213 allele; M2: heterozygous and homozygous for His101allele; no
M2: homozygous for Arg101 allele; M3: heterozygous and homozygous
for Asp376 allele; no M3: homozygous for Glu376 allele.
aStudent’s t test;
bPearson’s 
2 test.compared to healthy controls. We also verified that there is
no correlation between these alleles and the manifestation
of emphysema, since there was no difference in their distri-
butioninpatientswithbronchialandemphysematoustypes
ofCOPD.Furthermore,nosignificantrelationshipbetween
SERPINA1 polymorphisms and annual FEV1 decline eval-
uated over a two-year period in COPD patients was found.
To our knowledge, this is the first report on clinical mani-
festations of COPD in relation to common AAT variants.
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Table 4 - Association studies of lung function impairment with smoking,
body mass index (BMI), age and SERPINA1 genotypes.
Type/class FEV1 (mL/year) p
a
Smoking status
Never 151  131
Smoker 197  191 0.683
Cumulative cigarette consumption
< mean 164  179
> mean 230  194 0.197
BMI (kg/m
2)
< mean BMI 221  239
> mean BMI 178  144 0.408
Age
< mean age 165  109
> mean age 207  211 0.455
M1Ala 195  177
No M1Ala 194  205 0.983
a
M2 195  156
No M2 195  204 0.999
M3 205  212
No M3 187  152 0.726
Cumulative cigarette consumption = number of packs smoked per day
multiplied by years of consumption. M1Ala: heterozygous and homozy-
gous for Ala213 allele; no M1Ala: homozygous for Val213 allele; M2:
heterozygous and homozygous for His101 allele; no M2: homozygous for
Arg101 allele; M3: heterozygous and homozygous for Asp376 allele; no
M3: homozygous for Glu376 allele.
aStudent’s t test.